Screening for Intestinal Carriage of Extended-spectrum Beta-lactamase–producing Enterobacteriaceae in Critically Ill Patients: Expected Benefits and Evidence-based Controversies by Zahar, Jean-Ralph et al.
Screening for Intestinal Carriage of Extended-spectrum 
Beta-lactamase–producing Enterobacteriaceae  
in Critically Ill Patients: Expected Benefits and  
Evidence-based Controversies
Jean-Ralph Zahar,1,2 Stijn Blot,3,4 Patrice Nordmann,5,6,7 Romain Martischang,8 Jean-François Timsit,2,9 Stephan Harbarth,8 and François Barbier10 
1Infection Control Unit, Avicenne University Hospital, Assistance Publique - Hôpitaux de Paris, Bobigny, and 2INSERM, Infection Antimicrobial Modelling Evolution, UMR 1137, Paris Diderot, 
Sorbonne Paris Cité University, France; 3Department of Internal Medicine, Ghent University, Belgium; 4Burns, Trauma and Critical Care Research Centre, Centre for Clinical Research, Faculty of 
Medicine, University of Queensland, Brisbane, Australia; 5Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, INSERM European Unit and 6Swiss National 
Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, 7Institute for Microbiology, University of Lausanne and University Hospital Centre, and 8Infection Control 
Program and World Health Organization Collaborating Center, Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Switzerland; 9Medical and Infectious Diseases 
Intensive Care Unit, Bichat-Claude Bernard Hospital, APHP, Paris, and 10Medical Intensive Care Unit, La Source Hospital, Orléans, France
The rising burden of intensive care unit (ICU)-acquired infections due to extended-spectrum beta-lactamase–producing 
Enterobacteriaceae (ESBL-E) strengthens the requirement for efficient prevention strategies. The detection of intestinal carriage of 
ESBL-E through active surveillance cultures (ASC) and the implementation of contact precautions (CP) in carriers are currently 
advocated in most high-income countries, to prevent cross-transmission and subsequent ESBL-E infections in critically-ill patients. 
Yet, recent studies have challenged the benefit of ASC and CP in controlling the spread of ESBL-E in ICUs with high compliance 
to standard hygiene precautions and no ongoing outbreak of ESBL-producing Klebsiella pneumoniae or Enterobacter spp. Besides, 
given their debated performance to positively predict which patients are at risk of ESBL-E infections, ASC results appear of limited 
value to rationalize the empirical use of carbapenems in the ICU, emphasizing the urgent need for novel anticipatory and diagnostic 
approaches. This Viewpoint article summarizes the available evidence on these issues.
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The rising prevalence of intensive care unit (ICU)-acquired 
infections due to extended-spectrum beta-lactamase–produc-
ing Enterobacteriaceae (ESBL-E) and the human and economic 
costs that they induce intensify the necessity for efficient pre-
vention strategies [1]. Since the gut microbiome stands as the 
main reservoir of invasive ESBL-E strains, a search-and-isolate 
strategy, based on screening for intestinal carriage through 
active surveillance cultures (ASC) and the implementation 
of contact precautions (CP) in identified carriers, is currently 
advocated by international guidelines for ICUs facing ESBL-E 
endemicity or ongoing outbreaks [2, 3]. This policy primar-
ily aims at preventing the cross-transmission of strains and/
or ESBL-encoding plasmids and, thereby, subsequent ESBL-E 
infections in patients not colonized at admission. In addi-
tion, since prior colonization acts as a strong risk factor for 
ESBL-E infection, ASC results could assist the fine-tuning of 
empirical antibiotic therapy in critically-ill patients with sepsis 
by inciting intensivists to opt for carbapenems rather than other 
broad-spectrum beta-lactams in documented ESBL-E carriers 
[1, 4]. However, the benefit of ASC for controlling the spread 
of ESBL-E and rationalizing the use of carbapenems in the ICU 
has been increasingly challenged by the recent literature. In this 
short narrative review, we sought to summarize the available 
evidence on these issues.
ACTIVE SURVEILLANCE CULTURES AND 
CONTACT PRECAUTIONS IN THE CRITICAL CARE 
ENVIRONMENT
ESBL-E—notably, CTX-M–producing Escherichia coli—have 
globally disseminated in the community, with estimated car-
riage prevalences ranging from 2 to 12% in Europe, 5 to 47% in 
Africa, 7 to 44% in Southeast Asia, and 29 to 63% in the West 
Pacific area [5]. This pandemic drives a continuous influx of 
ESBL-E into the hospital system that adds to the pool of inpa-
tients colonized with healthcare-associated lineages. Thus, car-
riage prevalence at ICU admission is rapidly increasing, and 
now commonly reaches 10–15% in Europe and up to 40% in 
certain Asian countries [6], although marked fluctuations are 
observed depending on the hospital location and case mix 
(Supplementary Table S1). Of note, the prevalence of imported 
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carriage in a given ICU has been linked to the likelihood of 
ESBL-E acquisition among patients not colonized at admission, 
a phenomenon referred as to colonization pressure [7, 8]. This, 
along with variations in infection control policies, may explain 
why the average in-ICU acquisition rates remain quite limited 
in Europe and the Americas (ie, 3–4%) while exceeding 20% in 
high-prevalence areas [9] (Supplementary Table S1).
In addition to hand hygiene (HH) and other standard pre-
cautions, the concept of CP implies the utilization of single-bed 
rooms; patient-dedicated equipment; single-use gloves and 
gowns for healthcare workers during contacts with carriers 
or contaminated environments; and the signalization of car-
riage to ensure compliance [3]. Historically, CP have proven 
efficiency to control ICU outbreaks of hospital-associated 
ESBL-E clones, especially ESBL-producing Klebsiella pneumo-
niae and Enterobacter spp, both being associated with a more 
pronounced ability for patient-to-patient spreading than ESBL-
producing E. coli [10, 11]. The determinants of this observation 
are manifold. One may suggest that patients colonized with 
ESBL-producing K.  pneumoniae or Enterobacter spp. differ 
from those carrying ESBL-producing E. coli in terms of comor-
bidities and prior contacts with the healthcare system [12, 13]. 
This could reflect more requirements for nursing care and inva-
sive procedures, as well as more frequent antimicrobial expo-
sure (that is, a more severe intestinal dysbiosis, with a higher 
faecal relative abundance of ESBL-E), resulting in an increase 
in the probability of cross-transmission events. Also, prolonged 
environmental contamination is probably less of an issue with 
ESBL-producing E. coli than with other ESBL-E.
Yet, apart from epidemic situations, controversies have 
emerged on whether a systematic ASC and CP policy may 
help in preventing ESBL-E cross-transmission in hospital units 
applying current hygiene standards. Studies conducted in 
wards notably failed to demonstrate a superiority of CP to con-
tain the spread of ESBL-producing E. coli, when compared to 
standard precautions [14]. It has also been shown that ESBL-E 
cross-transmission occurs rarely—even in double-bed rooms—
in wards with a high level of compliance to standard precau-
tions [10, 15]. Similar results have been increasingly reported 
in the critical care setting over the recent years. In the European 
multi-ICU MOSAR trial, universal screening for the carriage 
of multidrug-resistant (MDR) Enterobacteriaceae (mostly 
non–E.  coli ESBL-E) and the implementation of CP in carri-
ers had no measurable added value on acquisition rates after 
a first educational phase that increased HH compliance from 
52 to 77% and included daily chlorhexidine body-washing 
[16]. The MOSAR investigators confirmed afterwards that the 
transmissibility of ESBL-E between ICU patients was actually 
weak, and was even 3 times lower for ESBL-producing E. coli 
when compared to other ESBL-E (number of secondary cases 
per index carrier: 0.047 and 0.17, respectively) [17]. These find-
ings corroborate those of several single-center studies based on 
molecular methods (strain and/or ESBL typing) that reported 
very low rates of cross-transmission from documented ESBL-E 
carriers, including in units without single-bed rooms, suggest-
ing other potential sources of acquisition, such as healthcare 
workers, contaminated environmental reservoirs, or patient 
transports outside the ICU [18, 19].
Contact isolation measures have been associated with a 
variety of deleterious side-effects, including patients’ psy-
chological distress and an increased hazard of adverse events 
or medical errors [20, 21]. Another key issue is the relatively 
high frequency of false-negative ASC samples—up to 25%—
due to incorrect rectal swabbing procedures or colonization 
densities of ESBL-E below the detection thresholds [10]. 
Next, a policy of universal ASC generates both a massive 
workload for laboratory staffs and substantial expenditures 
for the hospital system, although its health-economic bene-
fit has not been re-appraised in the contemporary epidemi-
ological context. However, in a dynamic model of ESBL-E 
dissemination in a 10-bed ICU with an assumed baseline 
acquisition rate of 15%, improving HH compliance before 
and after each contact with patients from 60% to 80% was 
more effective and cost saving than routine carriage screen-
ing and CP isolation [22].
The targeted screening of patients with pre-specified risk 
factors for ESBL-E carriage (ie, recent antimicrobial exposure 
and/or transfer from long-term care facilities, wards, or other 
ICUs, especially if abroad) appears as a potentially cost-saving 
alternative to extended ASC [23]. In 2 before-and-after stud-
ies conducted in French ICUs with rates of imported ESBL-E 
carriage in the range of those usually reported in Northern 
European countries (that is, 6–7%), switching from universal to 
targeted ASC had no impact on the incidence of ICU-acquired 
ESBL-E infections [24, 25]. Of note, patients admitted directly 
from home through the emergency department and without 
known predisposing factors for ESBL-E carriage may be colo-
nized by community-acquired ESBL-producing E.  coli. These 
patients would be missed by a policy of targeted screening; 
nonetheless, and as discussed above, the hazard of cross-trans-
mission from such unidentified carriers of ESBL-producing 
E.  coli is probably negligible, provided that standard precau-
tions are strictly applied. More pragmatically, in 2 recent studies 
conducted in ICUs with a relatively low prevalence of ESBL-E, 
high compliance to standard precautions, and only single-bed 
rooms, no change was observed in the incidence densities of 
ICU-acquired ESBL-E colonization and infection following 
the complete discontinuation of ASC and CP [26, 27], further 
raising doubt regarding the relevance of these measures in the 
absence of an outbreak. Still, ASC may be warranted for trans-
ferred or repatriated patients at high risk of carriage of carbap-
enemase-producing Enterobacteriaceae or other extensively 
drug-resistant Gram-negative bacteria (GNB), such as pan-re-
sistant Acinetobacter spp.
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ACTIVE SURVEILLANCE CULTURES DATA AND 
EMPIRICAL ANTIMICROBIAL THERAPY
ASC may provide relevant ecological insights at both indi-
vidual and ICU levels for the steering of empirical therapy 
in critically-ill patients. Yet, the relative risk of ICU-acquired 
ESBL-E infection is up to 50-fold higher in patients with a pre-
viously-documented ESBL-E carriage than in those without 
[9]. Considering that the impaired outcome associated with 
ESBL-E infections mainly ensues from ineffective first-line cov-
erage [28], the colonization status is understandably seen as a 
decisional tool to optimize the likelihood of adequate empir-
ical therapy in patients with suspected nosocomial sepsis [1]. 
Nevertheless, this approach fosters a massive over-consumption 
of carbapenems in carriers not infected with ESBL-E [4], which 
may then enhance the spread of non-fermenting GNB exhib-
iting intrinsic (eg, Stenotrophomonas maltophilia) or acquired 
(eg, Pseudomonas aeruginosa mutants with modified OprD 
porin) resistance to this antimicrobial class [29]. This excess use 
of carbapenems could also contribute to the ongoing pandemic 
of carbapenemase-producing Enterobacteriaceae [30], although 
definite evidence is still lacking to confirm this hypothesis.
Overall, ESBL-E infections occur during ICU stays in only 
10 to 25% of critically-ill patients with intestinal colonization 
[4, 6, 26, 31]. In those receiving mechanical ventilation, ESBL-E 
are responsible for ~40% of ventilator-associated pneumonia 
(VAP) [6, 32], while accounting for merely 7% of infection-re-
lated ventilator-associated complications [33]. Therefore, in an 
era of growing prevalence of colonization, identifying those 
carriers at risk for infection constitutes a pivotal challenge for 
carbapenem sparing in the ICU. Studies that focused on this 
issue yielded conflicting results on the predictive role of clin-
ical parameters, such as prior length of the ICU stay, previ-
ous exposure to non-carbapenem antimicrobials (including 
beta-lactam/beta-lactamase inhibitor combinations, third-gen-
eration cephalosporins, or fluoroquinolones), or imported ver-
sus ICU-acquired carriage [6, 31, 33]. Patients colonized with 
ESBL-producing K. pneumoniae or Enterobacter spp. are seem-
ingly at higher risk of infection than those colonized with ESBL-
producing E. coli [6, 11], an association that might depend on 
clinical features of the carriers rather than on differences in 
invasiveness between species. To date, except for the protective 
effect of a recent exposure to carbapenems, no reliable predic-
tor of ESBL-E infection may help limiting their empirical use 
in documented carriers [33]. Moreover, if the absence of doc-
umented colonization has a >90% negative predictive value 
for ESBL-E infections [34], it does not definitively rule out the 
involvement of such pathogens, due to the aforementioned pos-
sibility of a false-negative ASC or, more anecdotally, an acqui-
sition of carriage between the last available ASC sample and 
the occurrence of infection. Also, a negative ASC sample for 
ESBL-E does not exclude an infection caused by other carbape-
nem-requiring GNB (eg, ceftazidime-resistant P. aeruginosa or 
MDR Acinetobacter baumannii). It is especially noteworthy that 
roughly half of culture-positive VAP episodes in ESBL-E carri-
ers implicate non-fermenting GNB (including carbapenem-re-
sistant isolates), alone or in combination with ESBL-E [6, 32, 
33]. Hence, a policy of routine screening for intestinal carriage 
of ESBL-E appears of limited value to rationalize the use of car-
bapenems in ICU patients.
DEALING WITH THE EXTENDED-SPECTRUM BETA-
LACTAMASE–PRODUCING ENTEROBACTERIACEAE 
PANDEMIC: PERSPECTIVES FOR INTENSIVISTS
The prevalence of ESBL-E carriage at ICU admission and the 
resulting colonization pressure are expected to increase steadily 
in the years to come, unless strong counter-measures are taken. 
In this global endemic situation, universal interventions could 
more effectively prevent cross-transmission than a carrier-cen-
tred approach. Sustained efforts to ensure a high level of com-
pliance to HH (that is, above 80%) and other standard measures 
(eg, environmental disinfection and handling of excreta) are 
of paramount importance [35]. Overall, routine ASC and the 
implementation of CP should now be focused on highly-resis-
tant pathogens, such as vancomycin-resistant enterococci or 
carbapenemase-producing GNB.
Antimicrobial stewardship initiatives are equally essential, since 
avoiding agents that degrade the normal gut microbiome and 
the colonization resistance that it confers might protect against 
ESBL-E acquisition [1, 35]. It has notably been reported that prior 
exposure to beta-lactam/beta-lactamase inhibitor combinations, 
third-generation cephalosporins (3GC), fluoroquinolones, and 
even carbapenems may predispose patients to in-ICU acquisition 
of ESBL-E carriage [8, 9]. Along this line, comparative metage-
nomic-based studies are warranted to better appraise the impact 
of antimicrobials on the gut ecosystem, including for agents with-
out activity against Enterobacteriaceae but with a potent anti-an-
aerobe effect (eg, metronidazole) [36]. Antimicrobial adsorption 
in the intestinal lumen represents another promising track to 
reduce their ecological side effects [37].
New algorithms to restrain the empirical use of carbapenems 
in patients at risk for ESBL-E infection should be considered, 
given the poor specificity of qualitative ASC. Features of ESBL-E 
strains (especially virulence determinants) and those of the 
carrier’s gut microbiome (namely, richness and diversity) could 
putatively impact the hazard of infection [36]. Next-generation 
sequencing technologies may yield new insights on the virulome 
and invasiveness of a given ESBL-E strain—as well as its potential 
for patient-to-patient dissemination—although such markers will 
not be shortly available at a bedside [38]. Also, the faecal relative 
abundance of MDR pathogens—including ESBL-E—correlates 
with the likelihood of infection in non-ICU patients [39–41], 
suggesting a potential role for quantitative ASC in critically-ill 
carriers. Then, in mechanically-ventilated patients, oropharyngeal 
and lower respiratory tract surveillance cultures have been shown 
3
htt
p:/
/do
c.r
ero
.ch
to usefully predict the pathogens responsible for subsequent VAP 
[42, 43]; however, this point remains to be specifically addressed 
for ESBL-E VAP. Next, recently-released beta-lactam/beta-
lactamase inhibitor combinations (ie, ceftolozane-tazobactam 
and ceftazidime-avibactam) exhibit activity against multidrug-
resistant P. aeruginosa (including carbapenem-resistant isolates), 
as well as certain ESBL-E strains (particularly ESBL-producing 
E. coli) [44], and could theoretically be considered as empirical 
regimen when both pathogens are suspected. However, clinical 
and ecological data remain somewhat scarce in critically-ill 
patients [45], leaving space for further studies to define their 
potential role as first-line drugs.
On a short-term basis, rapid diagnostic tools stand as the 
most pragmatic option to detect or exclude an ESBL-E in clinical 
samples and customize the empirical regimen of ICU patients 
when an infectious event arises, or to allow earlier de-escalation in 
those initially treated with a carbapenem. These tests may first be 
based on chromogenic assays that rapidly detect 3GC-hydrolyzing 
enzymes (including ESBL) on clinical specimens or early cultures. 
Direct antimicrobial susceptibility testing (AST) on clinical 
samples (eg, broncho-alveolar lavage fluid for patients with 
suspected VAP) is another relevant approach, as it provides 
susceptibility data from 24 to 48 hours earlier than conventional, 
subculture-based AST. Moreover, several molecular assays, 
allowing the detection of ESBL-encoding genes on clinical samples, 
have been recently released. Although their accuracy still requires 
in-depth and multi-center appraisal in ICU patients, these tools 
raise major hopes for the improvement of antibiotic stewardship 
practices in this specific population. Table  1 summarizes the 
available evidence on the diagnostic performances and potential 
applications for these tests.
CONCLUSIONS
In an era of global ESBL-E dissemination and a massive influx of 
colonized patients in the ICU setting, we believe that infection 
prevention strategies should focus on universal measures—with 
the aim of ensuring a high level of compliance to HH and other 
standard precautions—and not on a search-and-isolate policy 
based on the detection of all ESBL-E carriers through intestinal 
ASC (Table 2). Targeted screening and CP remain a conceivable 
Table 1. Selection of Commercially Available or Homemade Diagnostic Tests for Earlier Detection of Extended-spectrum Beta-lactamase–producing 
Enterobacteriaceae in Clinical Samples
Diagnostic Tests Clinical Samples
Performance for ESBL-E  
Detection (Available Published Data)
Time From  
Sampling to Results
Selected  
References
β-Lacta Testa
(Bio-Rad, France),
chromogenic tests for the 
detection of 3GC-hydrolyzing 
enzymes (including ESBL)
Urine with GNB on DE; 
tracheal aspirate (MV patients) 
with GNB on DE and/or 
culture ≥ 10.4 cfu/mL; 
blood culture positive for GNB
Se 87–100%, Sp 100%; Se 100%, Sp 
100%, PPV 100%, NPV 100%;
Se 100%, Sp 96%, PPV 90%, NPV 100%
60–120 min (test, 15 min);
60–120 min (test, 15 min);
variableb (culture + 3-hour 
subculture + 15-min test)
[46]
[47]
[48]
Rapid ESBL NP Testc
(homemade),
chromogenic tests for the 
detection of 3GC-hydrolyzing 
enzymes (including ESBL)
Urine with GNB on DE; 
blood culture positive for GNB
Se 100%, Sp 99%, PPV 98%, NPV 99%;
Se 100%, Sp 100%, PPV 100%, NPV 
100%
60–120 min (test, 15 min)
Variableb (test, 30–45 min)
[49]
[50, 51]
Direct AST on respiratory 
sample without sub-culture 
(homemade)
Broncho-alveolar lavage (MV 
patients) with GNB on DE
Se 100%, Sp 95%, PPV 94%, NPV 100%
(values are for 3GC resistance in 
Enterobacteriaceae: ESBL and other 
mechanisms)
18–24 hours [52]
Verigene BC-GN
(Luminex), automated 
multiplex PCR for pathogen 
identiﬁcation and detection of 
blaCTX-M genes
Blood culture positive for GNB Se 80–93%, Sp 99–100%, NPV 
93–99%, PPV 97–100% (values are 
for Escherichia coli and Klebsiella 
pneumonia only)
Variableb (test, 2.5 hours) [53, 54]
Unyvero
(Curetis, Germany)
Automated multiplex PCR for 
pathogen identiﬁcation and 
detection of blaCTX-M genes
Tacheal aspirate and broncho-
alveolar lavage (HPN 
cartridge); blood culture 
(BCU cartridge);
urine (UTI cartridge)
Se 100%, Sp 85–95%, NPV 100%, PPV 
20–40% (values are for E. coli and 
K. pneumonia only); 
not published; 
not published
4–5 hours;
4–5 hours;
4–5 hours
[55]
…
…
Accelerate pheno system 
(Accelerate Diagnostics)
Automated FISH (pathogen 
identiﬁcation) and AST
Positive blood culture Agreement with culture-based 
AST for ceftriaxone resistance in 
Enterobacteriaceae, 95–97%
Variableb (test, 6–7 hours) [56, 57]
Abbreviations: 3GC, third-generation cephalosporins; AST, antimicrobial susceptibility testing; DE, direct examination; ESBL, extended-spectrum beta-lactamase; ESBL-E, ESBL-producing 
Enterobacteriaceae; FISH, ﬂuorescence in situ hybridization; GNB, Gram-negative bacteria; MV, mechanical ventilation; NPV, negative predictive value; PCR, polymerase chain reaction; PPV, 
positive predictive value; Se, sensibility; Sp, speciﬁcity.
aThe β-Lacta Test detects all cephalosporin-hydrolyzing enzymes, including ESBL; chromosomal and plasmid-borne AmpC cephalosporinases; and carbapenemases, which may decrease 
the speciﬁcity of this test for the detection of ESBL in settings where other cephalosporine-hydrolyzing beta-lactamases are prevalent. 
bDepending on the time to positivity of blood cultures (usually 6 to 12 hours for bloodstream infections, due to Enterobacteriaceae).
cThe Rapid ESBL NP Test only detects ESBL.
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approach in critical-care environments with uncontrolled 
endemicity or outbreaks of ESBL-producing K. pneumoniae or 
Enterobacter spp., while the available evidence argues against 
the usefulness of such interventions in ICUs where ESBL-
producing E.  coli predominate. Given the rising incidence of 
healthcare-associated infections due to carbapenem-resistant 
GNB, a paradigm shift from ACS-based empirical regimen to 
new diagnostic approaches is urgently needed to restrain the 
overconsumption of carbapenems in patients at risk for ICU-
acquired ESBL-E infections. The use of clinical algorithms, 
including rapid diagnostic tests, which are able to rule out the 
involvement of ESBL-E based on high negative predictive val-
ues, will probably help ICU physicians to choose the best thera-
peutic options in patients with suspected healthcare-associated 
infections.
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Table 2. Key Messages
• Rates of imported ESBL-E carriage are rapidly increasing in most ICUs worldwide, owing to the successful spread of these pathogens (especially CTX-M– 
producing E. coli) in both community and hospital ecosystems.
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